CAS
EW icon

CTC Alternative Strategies’s Edwards Lifesciences EW Stock Holding History

CTC Alternative Strategies’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,100
Closed -$328K – 106
2026
Q1 		$328K Buy
+4,100
New +$338K 0.75% 46
2025
Q4 		– Sell
-8,100
Closed -$630K – 58
2025
Q3 		$630K Buy
+8,100
New +$633K 1.02% 27
2024
Q3 		– Sell
-8,400
Closed -$776K – 115
2024
Q2 		$776K Buy
+8,400
New +$744K 0.33% 73

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CTC Alternative Strategies's EW Position: Q2 2026 in Review

CTC Alternative Strategies sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 4,100 shares — an estimated $328K sold.

CTC Alternative Strategies first reported a position in EW in Q2 2024 and held it in 3 quarters. The position peaked at $776K in Q2 2024. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • CTC Alternative Strategies reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • CTC Alternative Strategies sold 4,100 Edwards Lifesciences shares in Q2 2026, an estimated $328K.
  • CTC Alternative Strategies first reported a position in Edwards Lifesciences in Q2 2024 and held it in 3 quarters.
  • CTC Alternative Strategies's Edwards Lifesciences position peaked at $776K in Q2 2024.
  • 1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.